Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatments for NAFLD: State of Art
Alessandro Mantovani, Andrea Dalbeni
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 5, pp. 2350-2350
Open Access | Times Cited: 160

Showing 1-25 of 160 citing articles:

Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease
Fasiha Kanwal, Jay H. Shubrook, Leon A. Adams, et al.
Gastroenterology (2021) Vol. 161, Iss. 5, pp. 1657-1669
Open Access | Times Cited: 365
NAFLD: Mechanisms, Treatments, and Biomarkers
Fatiha Nassir
Biomolecules (2022) Vol. 12, Iss. 6, pp. 824-824
Open Access | Times Cited: 241
Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention
Xiaodong Zhou, Jingjing Cai, Giovanni Targher, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 95
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Xiaodong Zhou, Giovanni Targher, Christopher D. Byrne, et al.
Hepatology International (2023) Vol. 17, Iss. 4, pp. 773-791
Open Access | Times Cited: 83
The efficacy of sodium-glucose transporter 2 inhibitors in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis
Hongsheng Li, Yanli Hou, Xin Wang, et al.
Pharmacological Research (2025) Vol. 213, pp. 107647-107647
Open Access | Times Cited: 1
Perspectives in liver redox imbalance: Toxicological and pharmacological aspects underlying iron overloading, nonalcoholic fatty liver disease, and thyroid hormone action
Luis A. Videla, Rodrigo Valenzuela
BioFactors (2021) Vol. 48, Iss. 2, pp. 400-415
Closed Access | Times Cited: 60
Role of Mitochondrial Cytochrome P450 2E1 in Healthy and Diseased Liver
Julie Massart, Karima Begriche, Jessica H. Hartman, et al.
Cells (2022) Vol. 11, Iss. 2, pp. 288-288
Open Access | Times Cited: 56
The Interconnection between Hepatic Insulin Resistance and Metabolic Dysfunction-Associated Steatotic Liver Disease—The Transition from an Adipocentric to Liver-Centric Approach
Milena Vesković, Nikola Šutulović, Dragan Hrnčić, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 11, pp. 9084-9102
Open Access | Times Cited: 24
Metabolic Dysfunction-Associated Steatohepatitis and Progression to Hepatocellular Carcinoma: A Literature Review
Haider Ghazanfar, Nismat Javed, Abeer Qasim, et al.
Cancers (2024) Vol. 16, Iss. 6, pp. 1214-1214
Open Access | Times Cited: 12
The therapeutic perspective of NAD+ precursors in age-related diseases
Tooba Iqbal, Takashi Nakagawa
Biochemical and Biophysical Research Communications (2024) Vol. 702, pp. 149590-149590
Open Access | Times Cited: 11
Role of Resmetirom, a Liver-Directed, Thyroid Hormone Receptor Beta-Selective Agonist, in Managing Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis
Deep Dutta, A B Kamrul-Hasan, E Mondal, et al.
Endocrine Practice (2024) Vol. 30, Iss. 7, pp. 631-638
Closed Access | Times Cited: 11
Portal hypertension in patients with nonalcoholic fatty liver disease: Current knowledge and challenges
Anita Madir, Ivica Grgurević, Emmanuel Tsochatzis, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 4, pp. 290-307
Open Access | Times Cited: 10
Bacteroides and NAFLD: pathophysiology and therapy
Jun Zhang, Jing Zhou, Zheyun He, et al.
Frontiers in Microbiology (2024) Vol. 15
Open Access | Times Cited: 9
Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals
Matheus Souza, Ivanna Diaz, Lubna Al‐Sharif
Hepatology International (2024) Vol. 18, Iss. 5, pp. 1396-1415
Closed Access | Times Cited: 9
Histological improvements following energy restriction and exercise: The role of insulin resistance in resolution of MASH
Justine M. Mucinski, Amadeo F. Salvador, Mary P. Moore, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 5, pp. 781-793
Closed Access | Times Cited: 8
The impact of piperine on the metabolic conditions of patients with NAFLD and early cirrhosis: a randomized double-blind controlled trial
Masoud Nouri‐Vaskeh, Payam Hashemi, Naser Hataminia, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 7
Diabetes and metabolic dysfunction-associated fatty liver disease
Timothy M. E. Davis
Metabolism (2021) Vol. 123, pp. 154868-154868
Closed Access | Times Cited: 45
Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis
Kaneez Fatima, Abdul Moeed, Eisha Waqar, et al.
Clinics and Research in Hepatology and Gastroenterology (2021) Vol. 46, Iss. 4, pp. 101816-101816
Closed Access | Times Cited: 41
Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications
Amedeo Lonardo, Alessandro Mantovani, Giovanni Targher, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 13320-13320
Open Access | Times Cited: 36
MAFLD and CKD: An Updated Narrative Review
Alessandro Mantovani, Rosa Lombardi, Filippo Cattazzo, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 13, pp. 7007-7007
Open Access | Times Cited: 34
Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers
Rita Basu, Mazen Noureddin, Jeanne M. Clark
Mayo Clinic Proceedings (2022) Vol. 97, Iss. 9, pp. 1700-1716
Open Access | Times Cited: 34
Stearoyl-CoA desaturase 1: A potential target for non-alcoholic fatty liver disease?-perspective on emerging experimental evidence
Shanmugam M. Jeyakumar, Ayyalasomayajula Vajreswari
World Journal of Hepatology (2022) Vol. 14, Iss. 1, pp. 168-179
Open Access | Times Cited: 31
Statins’ efficacy in non-alcoholic fatty liver disease: A systematic review and meta-analysis
Chrysoula Boutari, Panagiotis D. Pappas, Dimitrios A. Anastasilakis, et al.
Clinical Nutrition (2022) Vol. 41, Iss. 10, pp. 2195-2206
Closed Access | Times Cited: 30
Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes
Alessandro Mantovani, Andrea Dalbeni, Giorgia Beatrice, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 4, pp. 968-968
Open Access | Times Cited: 28
Non-alcoholic fatty liver disease: Immunological mechanisms and current treatments
Lucy Petagine, Mohammed Gulrez Zariwala, Vinood B. Patel
World Journal of Gastroenterology (2023) Vol. 29, Iss. 32, pp. 4831-4850
Open Access | Times Cited: 19
Page 1 - Next Page

Scroll to top